ERBB2 and neoplasm: Its molecular biology and growing knowledge of tumor pathogenesis has allowed for the identification of several potential molecular targets including IGF-1 receptor antagonists, human epidermal growth factor receptor 2 (HER2)/neu receptor blockers, RANKL and bisphosphonate inhibitors, tyrosine kinase receptors targets, tyrosine kinase Src antagonists, VEGF inhibitors, immunomodulating agents, mammalian target of rapamycin (mTOR) inhibitors, MiRNA therapeutic targets, and signaling pathways and epigenetic regulators such as Hedgehog (Hh), Wnt/β-catenin, and Notch [30].